A pilot study to evaluate the safety and advantages of CurQfen on brain function in middle aged to elderly people.
- Registration Number
- CTRI/2018/03/012393
- Lead Sponsor
- Akay Flavours and Aromatics Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 6
1)Age 35-65 Years ( Both Inclusive)
2)Male and Female Subjects
3)Subjects in general good health.
4)Subjects with a MMSE score between 25 â?? 30
EXCLUSION CRITERIA
1)Subjects with a education qualification less than higher secondary level
2)Subjects who are not familiar with computer/internet use.
3)Subject with dementia/related memory loss illness
4)Subjects diagnosed with learning difficulty such as dyslexia or dyspraxia
5)Suffering from any form of clinically diagnosed disease, including:
oMajor mental illness (current or previous episode with hospitalization)
oChronic fatigue syndrome
oLiver disease
oDiabetes mellitus
oHeart disease or myocardial infarction
ounderwent brain surgery
owho have a central nervous system illness
oneurological lesion
6)Subjects with a known allergy to herbal products
7)Subjects with abnormal biochemical or haematological values
8)Subjects with abnormal blood pressure
9)Pregnant or Lactating Women
10)Any condition that in Opinion of the Investigator, does not justify the Subjectsâ?? participation in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Comparative changes EEG in basline and after administration of CurQfen <br/ ><br> <br/ ><br>-Comparative changes in cognitive assessment test scores <br/ ><br> <br/ ><br>Timepoint: Day 0, Day 15, Day 30
- Secondary Outcome Measures
Name Time Method - Change in Brain Derived Neurotrophic factor (BDNF) <br/ ><br>- safety of CurQfenTimepoint: Day 0, Day 30